Douglas Whittington
Company: Tango Therapeutics, Inc.
Job title: Executive Director, Biochemistry
Seminars:
Structure-Guided Drug Design of MTA-Cooperative PRMT5 Inhibitors 1:30 pm
- Highlight rationale for targeting MTA-bound PRMT5 in MTAP-deleted cancers
- Describe efforts informed by structure to convert SAM-cooperative PRMT5 inhibitors to MTA-cooperative PRMT5 inhibitors
- Highlight role of structural biology during efforts to advance a different chemical series from a modestly potent HTS hit to the clinical-stage MTA-cooperative PRMT5 inhibitors TNG908 and TNG462
day: Day 2
Panel Discussion: Bridging Medicinal & Computational Chemistry with Structural Insights for Smarter Drug Design 2:00 pm
- Overcoming challenges in integrating structural and computational approaches to advance from target identification to lead development
- Real-world success stories and lessons learned from projects were collaboration between disciplines significantly improved drug candidates
- Strategies for future-proofing drug discovery pipelines by embedding structural insights into medicinal and computational chemistry workflows
day: Day 1
